The effect of clomipramine treatment on plasma lipoproteins and high density lipoprotein subfractions in healthy subjects.
The effect of clomipramine on plasma lipoproteins, including high density lipoprotein (HDL) subfractions in five healthy males was investigated. The concentrations of total plasma cholesterol and low density lipoprotein cholesterol decreased slightly while that of total HDL-cholesterol showed a small increase, giving a decrease (p less than 0.05) in the ratio of total plasma cholesterol to HDL-cholesterol. The level of HDL2-cholesterol increased (p less than 0.01) with clomipramine treatment while there was no significant change in the concentration of HDL3-cholesterol. Gradient gel electrophoresis showed that administration of the drug was associated with an increase in the relative concentration of HDL2a as well as of HDL2b and a decrease in that of HDL3b/3c. The plasma concentration of apolipoprotein (Apo) A-I showed a small but insignificant increase. These changes in lipoprotein profile are characteristic of those associated with a decrease in coronary risk.
Skinner
E R
ER
Department of Biochemistry, University of Aberdeen, Scotland, UK.
Watt
C
C
Reid
I C
IC
Besson
J A
JA
Ashcroft
G W
GW
D000328:Adult; D001054:Apolipoproteins A / Q000097:blood; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood* / Q000145:classification; D008078:Cholesterol, LDL / Q000097:blood*; D002997:Clomipramine / Q000494:pharmacology*; D006801:Humans; D008297:Male; D014280:Triglycerides / Q000097:blood
D001054:Apolipoproteins A; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D002784:Cholesterol; D002997:Clomipramine